Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Overview of Therapeutic Effects of Statins on Inflammatory Diseases Through Regulating Adhesive Molecules

Author(s): Yibin Meng, Youhan Wang, Yibing li, Song Chon and Dingjun Hao*

Volume 15, Issue 7, 2020

Page: [614 - 622] Pages: 9

DOI: 10.2174/1574888X15666200225092749

Price: $65

Abstract

Simvastatin, lovastatin, rosuvastatin, pravastatin and cerivastatin belong to the statin family, which are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A. As the rate-limiting enzyme in the pathway of cholesterol metabolism, statins are classically prescribed to patients as lipidlowering agents. However, statins also possess several extra bioactivities, including anti-inflammatory, antiviral and anti-tumor. Interestingly, the most essential mechanism of these activities is that statins could regulate the expression of cell adhesion molecules (CAMs), especially, targeting lymphocytes function-associated molecules (LFA)-1, macrophage (Mac)-1 and intercellular adhesion molecules (ICAM)-1. Therefore, in this paper, we discussed the regulatory effect of statins on CAMs among different diseases. In addition, we provided speculation for the role of statins in treating orthopedic disease.

Keywords: Statins, inflammation, CAM, LFA-1, Mac-1, cardiovascular disease.

« Previous Next »
[1]
Freedman M, Quinn F, O’Sullivan M. Single unit CAD/CAM restorations: a literature review. J Ir Dent Assoc 2007; 53(1): 38-45.
[2]
Kapp TG, Rechenmacher F, Sobahi TR, Kessler H. Integrin modulators: a patent review. Expert Opin Ther Pat 2013; 23(10): 1273-95.
[http://dx.doi.org/10.1517/13543776.2013.818133]
[3]
Li N, Mao D, Lü S, Tong C, Zhang Y, Long M. 2013.
[4]
Bö L, Peterson JW, Mørk S, et al. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55(10): 1060-72.
[5]
Huang WR, Wang L. 2004.
[6]
Witkowska AM. Soluble ICAM-1: a marker of vascular inflammation and life-style. Cytokine 2005; 31(2): 127-34.
[7]
Griffiths H, Irundika D, Lip G, Spickett C, Polidori C. Oxidised LDL lipids, statins and a blood-brain barrier. Free Radic Biol Med 2014; 75(1): S15-6.
[http://dx.doi.org/10.1016/j.freeradbiomed.2014.10.591]
[8]
Sandhu K, Mamas M, Butler R. Endothelial progenitor cells: Exploring the pleiotropic effects of statins. World J Cardiol 2017; 9(1): 1-13.
[9]
Jin J, Machado ER, Yu H, et al. Simvastatin inhibits LPS-induced alveolar bone loss during metabolic syndrome. J Dent Res 2014; 93(3): 294-9.
[10]
Yamashita M, Otsuka F, Mukai T, et al. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 2010; 162(1-3): 99-108.
[11]
Gholipour S, Sewell RDE, Lorigooini Z, Rafieian-Kopaei M. Medicinal plants and atherosclerosis: A review on molecular aspects. Curr Pharm Des 2018; 24(26): 3123.
[http://dx.doi.org/10.2174/1381612824666180911121525]
[12]
Dippel V, Milde-Langosch K, Wicklein D, et al. Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells. J Cancer Res Clin Oncol 2013; 139(1): 107-21.
[13]
Fernández-Pisonero I, Dueñas AI, Barreiro O, Montero O, Sánchez-Madrid F, García-Rodríguez C. Lipopolysaccharide and sphingosine-1-phosphate cooperate to induce inflammatory molecules and leukocyte adhesion in endothelial cells. J Immunol 2012; 189(11): 5402-10.
[14]
Schmidt A, Goepfert C, Feitsma K, Buddecke E. ICAM-1 and VCAM-1 in TNF-alpha activated human vascular endothelial cells. Atherosclerosis 2002; 164(1): 57-4.
[15]
Landsberger M, Wolff B, Jantzen F, et al. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 2007; 190(1): 43-52.
[16]
Monetti M, Canavesi M, Camera M, et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 2007; 55(5): 441-9.
[http://dx.doi.org/10.1016/j.phrs.2007.02.001]
[17]
Du B, Xu G, Cao H, et al. Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits. J Cardiovasc Med (Hagerstown) 2013; 14(2): 120-6.
[18]
Takeuchi S, Kawashima S, Rikitake Y, et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 2000; 269(1): 97-102.
[19]
Anderson KP, Kern CB, Crable SC, Lingrel JB. Isolation of a gene encoding a functional zinc finger protein homologous to erythroid Krüppel-like factor: identification of a new multigene family. Mol Cell Biol 1995; 15(11): 5957-65.
[http://dx.doi.org/10.1128/MCB.15.11.5957]
[20]
Liu YS, Xu DL, Huang ZW, Hao L, Wang X, Lu QH. Atorvastatin counteracts high glucose-induced Krüppel-like factor 2 suppression in human umbilical vein endothelial cells. Postgrad Med 2015; 127(5): 446-54.
[21]
Okouchi M, Okayama N, Omi H, et al. Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation. J Diabetes Complications 2003; 17(6): 380-6.
[22]
Park J, Hwang I, Kim SJ, Youn SW, Hur J, Kim HS. Atorvastatin prevents endothelial dysfunction in high glucose condition through Skp2-mediated degradation of FOXO1 and ICAM-1. Biochem Biophys Res Commun 2018; 495(2): 2050-7.
[23]
Lin Y, Ye S, Chen Y, et al. The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats. J Diabetes Complications 2009; 23(3): 214-8.
[24]
Wu K, Tian S, Zhou H, Wu Y. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem Pharmacol 2013; 85(12): 1753-60.
[25]
Xenos ES, Stevens SL, Freeman MB, Cassada DC, Goldman MH. Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells. Ann Vasc Surg 2005; 19(3): 386-92.
[26]
Maruta K, Watanabe C, Hozumi H, et al. Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment. J Leukoc Biol 2018; 104(5): 1013-22.
[27]
Albaugh G, Bellavance E, Strande L, Heinburger S, Hewitt CW, Alexander JB. Nicotine induces mononuclear leukocyte adhesion and expression of adhesion molecules, VCAM and ICAM, in endothelial cells in vitro. Ann Vasc Surg 2004; 18(3): 302-7.
[28]
Cirillo P, Pacileo M, De Rosa S, et al. HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells. J Vasc Res 2007; 44(6): 460-70.
[29]
Canalli AA, Proença RF, Franco-Penteado CF, et al. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica 2011; 96(4): 526-33.
[30]
Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45(3): 283-6.
[31]
Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010; 29(7): 763-0.
[32]
Garg N, Krishan P, Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol 2015; 34(6): 1065-71.
[http://dx.doi.org/10.1007/s10067-015-2912-3]
[33]
Hölschermann H, Schuster D, Parviz B, Haberbosch W, Till-manns H, Muth H. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 2006; 185(2): 240-5.
[34]
Silveira AA, Dominical VM, Lazarini M, Costa FF, Conran N. Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity. Inflamm Res 2013; 62(2): 127-32.
[http://dx.doi.org/10.1007/s00011-012-0579-7]
[35]
Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7(6): 687-92.
[http://dx.doi.org/10.1038/89058]
[36]
Weitz-Schmidt G, Welzenbach K, Dawson J, Kallen J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J Biol Chem 2004; 279(45): 46764-71.
[37]
Lee JC, Yu MK, Lee R, et al. Terrein reduces pulpal inflammation in human dental pulp cells. J Endod 2008; 34(4): 433-7.
[38]
Jung JY, Woo SM, Kim WJ, et al. Simvastatin inhibits the expression of inflammatory cytokines and cell adhesion molecules induced by LPS in human dental pulp cells. Int Endod J 2017; 50(4): 377-86.
[39]
Oh EG, Bang SY, Kim SH, et al. Therapeutic lifestyle modification program reduces plasma levels of the chemokines CRP and MCP-1 in subjects with metabolic syndrome. Biol Res Nurs 2013; 15(1): 48-55.
[40]
Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 2009; 48(3): 233-42.
[41]
Montecucco F, Steffens S, Burger F, Pelli G, Monaco C, Mach F. C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. J Leukoc Biol 2008; 84(4): 1109-9.
[42]
Steffen BJ, Butcher EC, Engelhardt B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am J Pathol 1994; 145(1): 189-201.
[43]
Goc A, Kochuparambil ST, Al-Husein B, et al. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 2012; 12: 409.
[44]
Goc A, Liu J, Byzova TV, Somanath PR. Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β3 affinity modulation. Br J Cancer 2012; 107(4): 713-23.
[45]
Al-Husein B, Goc A, Somanath PR. Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. J Cell Physiol 2013; 228(11): 2139-48.
[46]
Sadaria MR, Reppert AE, Yu JA, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011; 142(5): 1152-60.
[47]
Fortin JF, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997; 71(5): 3588-96.
[48]
Bounou S, Leclerc JE, Tremblay MJ. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002; 76(3): 1004-4.
[49]
Giguère JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78(21): 12062-5.
[50]
Miao H, Jiang L, Huang L. Effects of simvastatin on the expression of intercellular adhesion molecule-1 mRNA in neonatal brain with hypoxic-ischemic damage. J Nanosci Nanotechnol 2005; 5(8): 1261-5.

Rights & Permissions Print Cite
Article Metrics
41
1
© 2024 Bentham Science Publishers | Privacy Policy